Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14.
learn about our pipelineAxsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.
learn about these CNS conditions & moreJuly 9, 2025
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
Click here to read moreJuly 7, 2025
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
Click here to read moreJune 20, 2025
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
Click here to read moreYou will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you are about to go to, which may not be appropriate for everyone.
